A Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Metastatic Colorectal Cancer
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Does the combination of oxaliplatin, 5-FU, leucovorin and capecitabine improve the activity of the FOLFOX regimens in metastatic colorectal cancer patients
Bi-monthly collection of information regarding tumor progression and overall survival.
Daniel Mulkerin, MD
University of Wisconsin, Madison
United States: Institutional Review Board
|University of Wisconsin||Madison,, Wisconsin 53792-5666|